Pathways & Perspectives with Alice Mims, MD
Meet Alice Mims, MD, a professor at The Ohio State University and senior medical director of the BeatAML study. Dr. Mims discusses venetoclax’s
Leukemia
Acute Myeloid Leukemia
News
18-IMCL
Meetings / Conferences
Income tied to survival outcomes in patients with DLBCL
A Finnish study found that patients with diffuse large B-cell lymphoma (DLBCL) who have low income levels have significantly worse survival outcomes.
Multiple Myeloma
A third of myeloma patients in remission more than 5 years after cilta-cel treatment
Long-term follow-up from the CARTITUDE-1 study showed that 33% of heavily pretreated patients with multiple myeloma (MM) were in remission for 5 or
Ambassador Program
News
Society Updates
SOHO regional meeting in Brazil delivers again
SOHO President Phillip Scheinberg, MD, PhD, head of the Division of Hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, wrote
18-IMCL
Vitamin D supplementation does not improve DLBCL outcomes
A study found that low baseline vitamin D is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL); however, supplementation
News
Society Updates
SOHO President Dr. Scheinberg drops hint on 2025 surprise
Phil Scheinberg, MD, PhD, chief of hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, shares his first impressions of
EHA 2025
Study supports frontline use of imetelstat for low-risk MDS patients ineligible for ESAs
A post-hoc analysis of pooled data from the IMerge trial found that patients with low-risk myelodysplastic syndromes (MDS) who were ineligible for erythropoiesis-stimulating
18-IMCL
News
ELARA trial: tisagenlecleucel response extends to 4 years in follicular lymphoma
Researchers presented 4-year follow-up data from the phase 2 ELARA study, showing that response to tisagenlecleucel continues to deepen in patients with follicular
2025 ASCO
Video Interviews
What do the real-world data show on luspatercept in LR-MDS?
In this video interview with Idoroenyi Amanam, MD, an assistant professor in City of Hope’s Division of Leukemia in the Department of Hematology
18-IMCL
News
GOLSEEK-1 phase 3 study of golcadomide for untreated LBCL
Golcadomide, an investigational first-in-class oral CELMoD, is being assessed in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients with high-risk